Key Highlights

  • PepGen jumped 159.83% to USD 6.21 on 67.27 million shares, a relative Volume of 65.22, with no catalyst identified in published coverage dated November 9 or 10, 2026.
  • Autonomix Medical gained 51.76% to USD 2.58 on 48.46 million shares, a relative volume of 522.06, against a Market Value of only USD 5.06 million.
  • Nano-X Imaging added 45.14% to USD 0.3391 on 20.6 million shares and still sits 92.4% beneath the USD 4.44 reached on November 21, 2025.
  • Humacyte advanced 28.08% to USD 0.5830 on results day, and Estrella Immunopharma climbed 26.48% to USD 0.6500, with no catalyst identified for Estrella.

PepGen (NASDAQ:PEPG): Up 159.83% With No Identified Catalyst

PepGen (NASDAQ:PEPG) closed at USD 6.21, up 159.83% from a calculated prior close of USD 2.39, and no release, filing or published coverage dated November 9 or 10, 2026 was identified. Volume was 67.27 million shares at a relative volume of 65.22, implying a recent average near 1.03 million shares and about USD 417.7 million traded (both calculated). As general context, a jump above 100% in a clinical-stage biotech typically follows data, a regulatory update, a deal, an Acquisition approach or a financing, none of which is confirmed here. The snapshot market value of USD 165.53 million lines up with a November 3 quote of USD 2.40, so size figures are unconfirmed. The 52-week range ran from USD 1.31 to USD 7.80 on November 3, which leaves the close near 80% of the high. At USD 6.21 the same share count would be worth roughly USD 430 million (calculated). Trailing EPS is USD -1.31. Equity raises often follow sharp rallies, and a move with no disclosed reason can retrace. Nothing indicates PepGen (NASDAQ:PEPG) will keep climbing.

Autonomix Medical (NASDAQ:AMIX): Up 51.76% With No Identified Catalyst

Autonomix Medical (NASDAQ:AMIX) closed at USD 2.58, up 51.76% from a calculated prior close of USD 1.70, and no release or filing dated November 9 or 10, 2026 turned up. Volume was 48.46 million shares at a relative volume of 522.06, about 24.7 times the whole share count (calculated). The shares had gained 11.84% on November 9, and cash was USD 9.9 million at December 31, 2025. The close sits 92.1% beneath the 52-week high of USD 32.55 (calculated). The newest items located were September 30, 2026 FDA pre-submission feedback supporting a 510(k) pathway and an early October Canadian patent, neither confirmed as the driver. As general context, pre-revenue device names leap on regulatory headlines, short covering or Social Media attention. Market value is USD 5.06 million, about 1.96 million shares (calculated), and the company points to a need for USD 30 million to USD 36 million more. A few trades can move Autonomix Medical (NASDAQ:AMIX), and dilution is a central risk.

Nano-X Imaging (NASDAQ:NNOX): Up 45.14% With No Identified Catalyst

Nano-X Imaging (NASDAQ:NNOX) closed at USD 0.3391, up 45.14% from a calculated prior close of USD 0.2336, and no results release, financing or analyst action dated November 9 or 10, 2026 turned up. Volume was 20.6 million shares at a relative volume of 20.05. At the prior close the market value was about USD 18.4 million (calculated). The latest dated background is the November 21, 2025 third-quarter report, with Revenue of USD 3.4 million, a loss of USD 13.7 million and 2026 revenue guidance of USD 35 million. As general context, sub-dollar stocks with deep losses often bounce on short covering or momentum. Market value is USD 26.7 million, about 78.7 million shares (calculated), but trailing EPS of USD -1.71 does not reconcile with that size and is unconfirmed. The close is 66.1% beneath USD 1.00, so Nasdaq bid price risk applies as a general rule. A few trades can move Nano-X Imaging (NASDAQ:NNOX), and the gain can reverse.

Humacyte (NASDAQ:HUMA): Up 28.08% on Third-Quarter Results Day

Humacyte (NASDAQ:HUMA) closed at USD 0.5830, up 28.08% from a calculated prior close of USD 0.4552, on the day it scheduled its third-quarter 2026 results and an 8:00 a.m. ET webcast. The figures in the release were not available for this review, and published coverage did not show which item drove the buying. Recent news included hospitals ordering Symvess growing 44%, from 34 to 49, as of September 30, a shelf life extension from 18 to 36 months and a first-in-human coronary bypass study. As general context, a stock under USD 1.00 often swings sharply on results days. A published snapshot cited about eight months of cash runway, which was not confirmed against a filing. Volume was 6.98 million shares at a relative volume of 1.62. Market value is USD 161.96 million, about 277.8 million shares (calculated), and trailing EPS is USD -0.49. New equity would dilute holders of Humacyte (NASDAQ:HUMA).

Estrella Immunopharma (NASDAQ:ESLA): Up 26.48% With No Identified Catalyst

Estrella Immunopharma (NASDAQ:ESLA) closed at USD 0.6500, up 26.48% from a calculated prior close of USD 0.5139, and published coverage dated November 9 or 10, 2026 identified no catalyst. Two searches turned up no results, trial data, financing, listing notice or analyst action. As general context, sub-dollar biotech shares can leap on a low float, social media attention or short covering. The company develops T-cell therapies at the pre-clinical stage, and the trailing loss of USD 0.25 per share equals about 38.5% of the share price (calculated). Market value is USD 28.27 million, and volume was 1.49 million shares at a relative volume of 1.53. The 52-week range ran from USD 0.295 to USD 3.15, so the close sits about 79.4% beneath the high (calculated). A few trades can move Estrella Immunopharma (NASDAQ:ESLA), dilution is a recurring risk, and nothing here suggests the move will continue.

Where Things Stand

The largest healthcare and biotech gainer on November 10, 2026 was PepGen (NASDAQ:PEPG), up 159.83% with no catalyst identified. The common thread across the five names is a share price under USD 7, small market values, losses and mostly no identified catalyst, with Humacyte the one that coincided with results. For Canadian investors following US biotech, large one-day gains in thinly traded names can reverse in the next session because a few trades set the price and funding needs invite dilution. The rankings rest on a published screener snapshot of the November 10, 2026 regular session, and several figures are calculated.